What Pharmosa Biopharm does

Pharmosa Biopharm Inc. is a Taiwan-based clinical-stage biopharmaceutical company specializing in proprietary sustained-release liposomal drug formulations combined with inhalation device technology. Founded in 2016 and publicly listed on the Taipei Exchange (TPEx) under stock code 6875 since February 2022 (with main board listing in March 2024), the company operates two core product candidates: L606, a liposomal inhaled treprostinil formulation in global Phase III development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and L608, a liposomal iloprost formulation in Phase I/II development for systemic sclerosis-associated Raynaud's phenomenon and digital ulcers (SSc-RP/DU), which received FDA Orphan Drug Designation in December 2023. The company's four-pillar technology platform encompasses sustained-release liposomal encapsulation, inhalation formulation compatible with MDIs, SMIs, and nebulizers, drug-device combination products, and scale-up manufacturing from laboratory to commercial scale.

Pharmosa generates revenue through a licensing and partnership model rather than direct commercialization. The company has established exclusive licensing agreements with Liquidia Corporation (NASDAQ: LQDA) covering North America, Europe, Japan and other territories for L606 (with $13.5M in upfront payments received and up to $372.75M in potential milestones plus low double-digit royalties), and with Menagen covering the MENAT region (Middle East, North Africa, Turkey). Revenue streams include upfront payments, development and sales milestone payments, royalties on net sales, and clinical supply revenue from cGMP manufacturing of clinical trial materials. The company retains manufacturing responsibility while licensees handle clinical development, regulatory activities, and commercialization in their respective territories. Approximately NT$1.2 billion (~$38M USD) in remaining R&D milestone payments are expected to be recognized progressively as clinical development advances.

The company serves patients with pulmonary vascular diseases (PAH and PH-ILD, with ~45,000 diagnosed US PAH patients and 60,000+ US PH-ILD patients) and peripheral vascular diseases (systemic sclerosis complications), targeting improved dosing convenience and reduced side effects compared to existing short-acting therapies. With 11-50 employees and headquarters at Taipei Bio-Tech Park, Pharmosa has received multiple industry recognitions including the 2024 Taipei Biotechnology Gold Award, 2024 Taiwan BIO Potential Benchmark Award, and 2023 Benchmark Enterprise Award.

Name

Pharmosa Biopharm

Legal name

Pharmosa Biopharm Inc.

Website

https://pharmosa.com.tw

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharmosa Biopharm is a Taiwan-based clinical-stage biopharmaceutical company developing proprietary sustained-release liposomal drug formulations paired with inhalation devices, licensing its lead candidates L606 (for PAH/PH-ILD) and L608 (for systemic sclerosis) to international partners including Liquidia and Menagen.

Ownership category

akta.pro rank

Product category

Specialty biopharmaceuticals (inhaled prostacyclin therapies)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Liposomal drug delivery
• Sustained release formulations
• Inhaled pharmaceuticals
• Drug-device combination
• Pulmonary hypertension therapeutics

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Revenue - North America (Liquidia): Pharmosa receives upfront payment ($10M), development milestones and sales milestones (up to $215M), and low double-digit royalties on net sales in North America from Liquidia for L606. Additional $10M milestone payment for each additional indication and each additional product approved.
2. Licensing Revenue - Europe/Japan/Other (Liquidia): Expanded agreement with Liquidia includes $3.5M upfront payment and up to $157.75M in additional development and sales milestones tied to commercial sales outside of North America (Europe, Japan and elsewhere).
3. Licensing Revenue - MENAT Region (Menagen): Menagen exclusively licenses MENAT rights to L606. Pharmosa receives upfront and milestone payments and royalties from Menagen. Pharmosa supplies commercial products with the ratio of high two figures of the end user price to Menagen.
4. Clinical Supply Revenue: Pharmosa manufactures and supplies clinical trial materials for L606 to Liquidia during global Phase III trials. Revenue grows as enrollment expands.
5. Milestone Payments: Near NT$1.2 billion (approximately NT$12 billion) in remaining R&D milestone payments to be recognized progressively as clinical development progresses.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Pharmosa Biopharm develops proprietary liposomal sustained-release drug formulations and combines them with proprietary inhalation and injection devices to create drug-device combination products. Its lead clinical assets are L606, a liposomal inhaled treprostinil formulation in Phase III for pulmonary arterial hypertension and PH-ILD, and L608, a liposomal iloprost formulation in development for systemic sclerosis-related Raynaud's phenomenon and digital ulcers. The company commercializes these assets by licensing them to international pharmaceutical partners while manufacturing and supplying clinical and commercial product under cGMP.

Product overview

Pharmosa Biopharm is a drug delivery company combining drug and device into unified products. The company operates two core products: L606 (liposomal treprostinil inhalation suspension for PAH and PH-ILD) and L608 (liposomal formulation for peripheral vascular conditions and PAH), both utilizing proprietary sustained-release liposomal formulation combined with inhalation devices. The company leverages four technology pillars: Sustained Release (liposomal formulation), Inhalation Formulation, Drug-Device Combination products, and Scale-up Production capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• L606 (liposomal inhaled treprostinil) Lipid-encapsulated, sustained-release inhaled treprostinil formulation for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD); designed to reduce dosing frequency from 4x to 2x daily with lower peak plasma concentration and reduced cough versus reference listed drug. Licensed to Liquidia (North America, Europe, Japan and other) and Menagen (MENAT region).
• L608 (liposomal iloprost) Lipid-encapsulated iloprost formulation in development for systemic sclerosis-associated Raynaud's phenomenon (SSc-RP) and digital ulcers (SSc-DU), and also in development for PAH. Uses liposomal formulation with inhalation delivery. Granted FDA Orphan Drug Designation providing 7 years of market exclusivity upon approval.

Quantifiable outcome

• L606 pharmacokinetics: 7x lower peak plasma concentration vs Tyvaso while maintaining therapeutic levels up to 12 hours
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Zai Lab Limited: Zai Lab (NASDAQ: ZLAB) is a China-US biotech that licenses in global assets for development and commercialization in Asia. Comparable asset-light Asian-rooted licensing and commercialization model, with broader therapeutic scope across oncology and autoimmune diseases.
• Vectura Group: Vectura (a Philip Morris subsidiary) is a broader inhalation drug delivery platform company offering formulation and device technology to pharma partners. Comparable business model in inhalation device/formulation combinations for inhaled therapeutics, though at larger scale and broader scope.
• Everest Medicines: Everest Medicines (HKEX: 1952) is an Asia-Pacific focused biopharma that in-licenses assets from global innovators. Comparable Asia-anchored licensing-driven business model with a portfolio approach across multiple therapeutic areas.

Direct peers

• Aradigm Corporation: Aradigm develops inhaled liposomal formulations (AERx, Pulmaquin) using proprietary sustained-release pulmonary delivery technology. Highly comparable as a liposomal inhalation platform targeting serious respiratory diseases, though Aradigm has historically been sub-scale.
• United Therapeutics Corporation: United Therapeutics (NASDAQ: UTHR) markets Tyvaso (inhaled treprostinil), the incumbent reference drug L606 is designed to improve upon. Direct competitor in PAH and PH-ILD with established physician relationships and a deep pipeline including Tyvaso DPI.
• Insmed Incorporated: Insmed (NASDAQ: INSM) is a specialty biopharma with proprietary inhaled drug delivery technology (liposomal and particle-based) and clinical/commercial infrastructure. Comparable as a focused inhalation-platform company developing reformulated drugs for serious lung diseases.

Regional players

• Lumosa Therapeutics: Lumosa Therapeutics is a Taiwan-listed (TPEx) specialty biopharma developing new chemical entities for neurological and inflammatory indications. Comparable as a Taiwan-listed specialty pharmaceutical peer pursuing innovative small-molecule drug development.
• OBI Pharma: OBI Pharma is a Taiwan-listed (TPEx) oncology and specialty biopharma developing innovative therapeutics including antibody-drug conjugates. Comparable as a Taiwan-listed specialty biopharma pursuing innovative drug development with global licensing ambitions.
• TaiMed Biologics: TaiMed Biologics is a Taiwan-listed specialty biopharma (TPEx) developing biologics and specialty drugs. Comparable as a Taiwan-based specialty pharmaceutical company listed on TPEx pursuing innovative drug development, though focused on biologics/antibody therapeutics.

Others

• Liquidia Corporation: Liquidia (NASDAQ: LQDA) is Pharmosa's exclusive licensing partner for L606 in North America, Europe, and Japan. While commercially aligned rather than competitive, Liquidia also develops inhaled treprostinil products in adjacent indications, placing it in a closely overlapping PAH therapeutic space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmosa-biopharm-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmosa Biopharm